伊立替康或依托泊苷联合顺铂一线治疗广泛期小细胞肺癌的疗效比较被引量：4

Comparison of safety and efficacy of irinotecan or etoposide combined with cisplatin as firstline treatment for extensive stage small cell lung cancer

暂未订购

导出

摘要目的比较伊立替康联合顺铂（irinotecanpluscisplatin，IP）与依托泊苷联合顺铂（etoposidepluscisplatin，EP）两种方案一线治疗广泛期小细胞肺癌（extensive．diseasesmallcelllungcancer，ED—SCLC）的临床疗效和毒副反应。方法初治ED．SCLC患者50例，予IP方案治疗25例，顺铂（DDP）30mg／mz静脉滴注，d1～d3；伊立替康（CPT．11）150mg／m2静脉滴注，dl；予EP方案治疗25例，DDP30mg／m。静脉滴注，d1．d3；依托泊苷（Vp-16）60mg／m。静脉滴注，d1～d5，两种方案均以21d为1个周期，连续化疗4个周期，每2个周期评价疗效及毒副反应。结果IP方案和EP方案有效率分别为72．0％、64．0％，差异无统计学意义（P=O．544）；两种方案血液学毒性发生率的差异无统计学意义（P〉0．05），但IP方案腹泻发生率明显高于EP方案（P=0．002）。结论伊立替康联合顺铂或依托泊苷联合顺铂一线治疗广泛期小细胞肺癌的疗效相似，患者均可耐受。 Objective To compare the clinical efficacy and adverse effects of the combination of irinotecan and cisplatin （IP） with the combination of etoposide and cisplatin （EP） as first-line therapy regimen for extensive-disease small cell lung cancer （ED-SCLC）. Methods ED-SCLC patients were assigned to receive IP （n =25;150 mg/m2 irinotecan on day 1 and 30 mg/m2 cisplatin on days 1-3 ） or EP （n=25; 60 mg/m2 etoposide on days 1-5 and 30 mg/m2 cisplatin on days 1-3 ）. Treatments were repeated every 3 weeks for a total of 4 cycles. Clinical efficacy and adverse effects were assessed every 2 cycles. Results Response rates（RR） were 72% with IP and 64% with EP （P=0.544）. The two regimens were associated with a similar rate of hematologic toxicity（P〉0.05）, while the IP regimen was associated with a significantly higher rate of diarrhea（P=0.002）. Conclusion Clinical efficacy may be similar for IP and EP as first-line therapy for ED-SCLC, and adverse effects appear to be tolerable in both cases.

作者柏峰方献英宋波张宇

机构地区河南省信阳市中心医院肿瘤内科二病区

出处《中国癌症防治杂志》 CAS 2016年第2期122-125,共4页 CHINESE JOURNAL OF ONCOLOGY PREVENTION AND TREATMENT

关键词肺肿瘤伊立替康依托泊苷顺铂化疗疗效 Lung neoplasm Irinotecan Etoposide Cisplatin Chemotherapy Efficacy

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献14

1王慧娟,闫相涛,路平,张桂芳,王俊生,吴涛,徐志巧,郭莲香,王居峰,杨树军,罗素霞,马智勇.伊立替康联合顺铂与依托泊苷联合顺铂方案一线治疗广泛期小细胞肺癌的多中心临床研究结果[J].中国癌症杂志,2011,21(10):783-788. 被引量：38
2杨新杰,张卉,农靖颖,王敬慧,李曦,张权,秦娜,张树才.伊立替康或足叶乙甙联合顺铂方案一线治疗小细胞肺癌的临床随机对照研究[J].中国肿瘤临床,2012,29(13):923-926. 被引量：8
3尹良伟,马海英,王颖,杜晓红.顺铂联合依托泊苷或伊立替康及拓扑替康一线治疗小细胞肺癌的比较研究[J].中华肿瘤防治杂志,2013,20(10):782-785. 被引量：9
4刘雅雯,熊建萍.伊立替康联合奈达铂一线治疗广泛期小细胞肺癌的临床观察[J].中国癌症防治杂志,2011,3(2):153-155. 被引量：6
5Van Meerbeeck JP, Fennell DA, De Ruysscher DK.Small-cell lung cancer[J].Lancet, 2011,378(9804): 1741-1755.
6Noda K,Nishiwaki Y,Kawahara M,et al.Irinotecan plus cisplatin compared with etoposide plus eisplatin for extensive small-cell lung caneer[J].N Engl J Med, 2002,346(2 ) : 85-91.
7Schmittel A,Fischer von Weikersthal L, Sebastian M,et al.A ran- domized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small- cell lung cancer[ J ].Ann Oncol, 2006,17(4) : 663-667.
8Hanna N,Bunn PA Jr,Langer C, et al. Randomized phase Ⅲ trial comparing irinotecan/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer[J].J Clin Oncol,2006, 24(13) :2038-2043.
9Lara PN Jr, Natale R, Crowley J, et al.Phase Ⅲ trial of irinotecan/cis- platin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer:clinical and pharmacogenomic results from SWOG S0124[J].J Clin Oncol,2009,27(15) :2530-2535.
10Hermes A,Bergman B, Bremnes R,et al. Irinotecan plus carboplatin venus oral etoposide plus carboplatin in extensive small-cell lung cancer: A randomized phase Ⅲ trial[ J ].J Clin Oncol, 2008,26(26) : 4261-4267.

二级参考文献58

1潘登,侯梅,李慧,余萍,刘建伟.伊立替康联合顺铂方案与足叶乙甙联合顺铂方案治疗小细胞肺癌的随机对照临床研究[J].中国肺癌杂志,2006,9(5):443-446. 被引量：16
2Cao W, Xu C, Lou G, et al. A Phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer[ J]. Japanese journal of clinical oncalogy,2009, 39(9) : 582.
3Zheng J, Wang G, Yang GY, et ah Induction chemotherapy with nedaplatin with 5-FU followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma[ J]. Japanese Journal of clinical oncology,2010, 40(5) : 425.
4Roth BJ, Johnson DH, Einhorn LH,et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive smallcen lung cancer: a phase III trial of the Southeastern Cancer Study Group[J]. Journal of clinical oncology, 1992, 10(2) :282.
5Sundstrom S. Cisplatin and etoposide regimen Is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase IIl trial with 5 years'follow-Up [ J ]. Journal of clinical oncology,2002, 20(24) : 4665-4672.
6Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer[ J ]. New England Journal of Medicine,2002, 346(2) : 85-91.
7Latorre A, DE L. Epithelial ovarian cancer : Second and third line chemotherapy (Review) [ J]. Intematianal joumal of oncology,2002, 21 ( 1 ) : 179-186.
8Simon G, Ginsberg R J, Ruckdeschel JC. Small-cell lung cancer [ J ]. Chest Surgery Clinics of North America,2001, 11 (1) : 165.
9Simon M, Argirls A, Murren JR. Progress in the therapy of small cell lung cancer [ J ]. Critical reviews in oncology/hematology, 2004, 49 ( 2 ) : 119-133.
10Hanna N, Bunn PA, Langer C, et al. Randomized phase 1II trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreat- ed extensive-stage disease small-cell lung cancer[J]. Journal of clinical oncology,2006, 24(13) : 2038.